Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Harpoon Therapeutics Inc
NASDAQ HARP
Data sourced from
and
and
Download Data
Harpoon Therapeutics Inc Price to Operating Income Ratio (P/OI) on March 11, 2024: -22.11
Harpoon Therapeutics Inc Price to Operating Income Ratio (P/OI) is -22.11 on March 11, 2024, a -5,999.58% change year over year. The price to operating income ratio compares the market price per share of a company's stock to its operating income per share. It is calculated by dividing the market capitalization by the operating income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's operating income generation. A higher ratio suggests that investors are willing to pay a higher price for each unit of operating income, indicating positive market sentiment and expectations for future profitability.
-
Harpoon Therapeutics Inc 52-week high Price to Operating Income Ratio (P/OI) is -0.34 on May 01, 2023, which is 98.45% above the current Price to Operating Income Ratio (P/OI).
-
Harpoon Therapeutics Inc 52-week low Price to Operating Income Ratio (P/OI) is -22.11 on March 11, 2024, which is 0.00% below the current Price to Operating Income Ratio (P/OI).
-
Harpoon Therapeutics Inc average Price to Operating Income Ratio (P/OI) for the last 52 weeks is -6.29.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: HARP
| CEO | Ms. Julie M. Eastland M.B.A. |
| IPO Date | Feb. 8, 2019 |
| Location | United States |
| Headquarters | 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Employees | 53 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Key trends
Similar companies
Stoke Therapeutics Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email